{
    "clinical_study": {
        "@rank": "146223", 
        "arm_group": [
            {
                "arm_group_label": "755nm Alexandrite Laser with Handpiece  2", 
                "arm_group_type": "Experimental", 
                "description": "Focusing energy on skin"
            }, 
            {
                "arm_group_label": "755nm Alexandrite Laser with handpiece 3", 
                "arm_group_type": "Experimental", 
                "description": "Focusing energy on skin"
            }, 
            {
                "arm_group_label": "755nm Alexandrite laser with handpiece 1", 
                "arm_group_type": "Experimental", 
                "description": "Focusing energy on skin"
            }
        ], 
        "brief_summary": {
            "textblock": "Compare efficacy and safety of handpieces on the 755nm Alexandrite laser for the treatment\n      of scars."
        }, 
        "brief_title": "Clinical and Histological Evaluation of the 755nm Alexandrite Laser With Handpiece for the Treatment of Scars", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Scars", 
        "condition_browse": {
            "mesh_term": "Cicatrix"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is a healthy male or female between 18 and 85 years old\n\n          2. Has unwanted scars not including atrophic scars and wishes to undergo laser\n             treatments.\n\n          3. Is willing to consent to participate in the study.\n\n          4. Is willing to comply with all requirements of the study including biopsies, being\n             photographed, following post treatment care and attending all treatment and follow up\n             visits.\n\n          5. Has Fitzpatrick skin types I to IV.\n\n        Exclusion Criteria:\n\n          1. The subject is female and pregnant, has been pregnant within the last 3 months, is\n             currently breast feeding or planning a pregnancy during the study period.\n\n          2. The subject is hypersensitive to light exposure OR takes photo sensitized medication.\n\n          3. The subject has active or localized systemic infections.\n\n          4. The subject has a coagulation disorder or is currently using anti-coagulation\n             medication (including but not limited to heavy aspirin therapy {greater than 81 mg\n             per day}).\n\n          5. The subject has any condition which, in the investigator's opinion, would make it\n             unsafe for the subject to participate in this research study.\n\n          6. The subject is currently enrolled in an investigational drug or device trial, or has\n             received an investigational drug or been treated with an investigational device\n             within 3 months prior to entering this study.\n\n          7. The subject has used Accutane within 6 months prior to enrollment.\n\n          8. The subject has the need to be exposed to artificial tanning devices or excessive\n             sunlight during the trial.\n\n          9. The subject has had prior treatment with parenteral gold therapy (gold sodium\n             thiomalate).\n\n         10. The subject has a history of keloids.\n\n         11. The subject has evidence of compromised wound healing.\n\n         12. The subject has a history of squamous cell carcinoma or melanoma.\n\n         13. The subject has a history of immunosuppression/immune deficiency disorders (including\n             HIV infection or AIDS) or use of immunosuppressive medications.\n\n         14. The subjects has an allergy to lidocaine and epinephrine."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813786", 
            "org_study_id": "CYN12-PICO-CAPHST-07"
        }, 
        "intervention": [
            {
                "arm_group_label": "755nm Alexandrite Laser with Handpiece  2", 
                "description": "Focusing energy on skin", 
                "intervention_name": "755nm Alexandrite Laser with handpiece 2", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "755nm Alexandrite laser with handpiece 1", 
                "description": "focusing energy at skin surface", 
                "intervention_name": "755nm Alexandrite Laser with handpiece 1", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "755nm Alexandrite Laser with handpiece 3", 
                "description": "Focusing energy on skin", 
                "intervention_name": "755nm Alexandrite Laser with handpiece 3", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "Laser & Skin Surgery Center of New York"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "other_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 3 months post last treatment"
        }, 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Histological examination of tissue samples will be compared between baseline and 3 months post treatment.", 
            "measure": "Subject Biopsy Sampling", 
            "safety_issue": "Yes", 
            "time_frame": "3 months post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813786"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "2D photographs to be taken at each visit and assessed at the end of the study by 2-3 blinded assessors for improvement.", 
                "measure": "Photographic evaluation as a measure of improvement.", 
                "safety_issue": "No", 
                "time_frame": "up to 3 months post last treatment"
            }, 
            {
                "description": "Histological examination of tissue samples will be compared between baseline and 2 weeks post treatment.", 
                "measure": "Subject Biopsy Sampling", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks post treatment"
            }, 
            {
                "description": "Histological examination of tissue samples will be compared between baseline and 1 month post treatment.", 
                "measure": "Subject Biopsy Sampling", 
                "safety_issue": "Yes", 
                "time_frame": "1 month post treatment"
            }
        ], 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}